Zdrowie i gospodarka · 30/10/2017

FDA Classifies Newborn Screening Test for Severe Combined Immunodeficiency Disorder into Class II with Special Controls

The FDA has classified the newborn screening test for severe combined immunodeficiency disorder (SCID) into Class II with special controls, aiming to ensure safety and effectiveness while reducing regulatory burdens and enhancing patient access to innovative devices.